If sufficient to secure approval, the data would give BMS an opportunity to take Breyanzi into so-far uncharted territory for CAR-Ts, which analysts at Clarivate have suggested could push the ...

Bristol-Myers Squibb has become the latest drugmaker in the US to file a legal challenge to a block ... Specifically, BMS is taking issue with a decision to deny its rebate plan for big-selling ...